Procaterol

DB01366ApprovedWithdrawnSmall molecule

Procaterol is a beta-2 adrenergic receptor agonist and bronchodilator used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

Chemical structure of Procaterol
Mechanism
Curator reviewed
Primary indication
For the treatment of asthma and chronic obstructive pulmonary disease (COPD).Curator reviewed · 4 structured indications
Formula / weight
C16H22N2O3 · 290.363 g/mol (avg)
First approval
Canada, 1989

Resolves to

Compound
UNIIX7I3EMM5K0CAS72332-33-3ChEMBLCHEMBL3249705ChEBI135209PubChem688561
Clinical / RWD
RxNorm34530ATCR03AC16ATCR03CC08PharmGKBPA164748908
Structure
InChIKeyFKNXQNWAXFXVNW-WBMJQRKESA-NSMILESCC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2
Targets
P07550ADRB2

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
819Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
28Marketed productsAcross 4 countries and 12 labellers
Sign in
2ATC codesIncluding every combination product, plus 24 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Procaterol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In